---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-290638"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:47:12.229903+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# XOMA completes acquisition of LAVA Therapeutics for $1.04/share plus CVRs

## Summary
- Subsequent Offering Period expired Nov 20, 2025; Post-Offer Reorganization effective same day.
- All LAVA shareholders who did not tender receive cash ($1.04/share) and one CVR for future payments.
- XOMA will file LAVA's financial statements and pro forma info in an amendment to this 8-K.

## SEC filing metadata
- accession: 0001193125-25-290638
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312525290638/0001193125-25-290638-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312525290638/d65279d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-290638
- JSON: https://secwatch.observer/filing/0001193125-25-290638.json
- Plain text: https://secwatch.observer/filing/0001193125-25-290638.txt

## Source-grounded claims
- claim_id: daa1bb000ee9e6d1a7d3adabda16736ef7fa3919
  claim: XOMA Royalty Corp completed an acquisition involving LAVA Therapeutics N.V. (closed 2025-11-20).
  evidence_excerpt: XOMA and LAVA effectuated the Post-Offer Reorganization, which became effective on November 20, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/791908/000119312525290638/0001193125-25-290638-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.